All In Biotech

Drug Trial Radar · NCT00387088

Tiotropium / Respimat One Year Study in COPD.

Efficacy {FEV1, COPD Exacerbations & HRQoL} & Safety of 5mcg Tiotropium Respimat in COPD

Last checked: Nov 20, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,991

Actual

Start

Sep 2006

Primary completion

Jan 2009

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Oct 12, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • RespimatDevice

  • TiotropiumDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337Time frame: Baseline and Day 337
  2. Time to First Chronic Obstructive Pulmonary Disease (COPD) ExacerbationTime frame: During actual study treatment period (planned Day 1 to Day 337)

Locations

334 sites in 31 countries. Site status is shown where the registry gives one.

  • 205.372.01012 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.372.01020 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.372.01062 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 205.372.01048 Boehringer Ingelheim Investigational Site

    Berkeley, California

  • 205.372.01037 Boehringer Ingelheim Investigational Site

    Huntington Park, California

  • 205.372.01058 Boehringer Ingelheim Investigational Site

    Long Beach, California

  • 205.372.01059 Boehringer Ingelheim Investigational Site

    Long Beach, California

  • 205.372.01007 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 205.372.01034 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 205.372.01028 Boehringer Ingelheim Investigational Site

    Rancho Mirage, California

  • 205.372.01011 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 205.372.01066 Boehringer Ingelheim Investigational Site

    Boulder, Colorado

  • 205.372.01008 Boehringer Ingelheim Investigational Site

    Norwalk, Connecticut

  • 205.372.01004 Boehringer Ingelheim Investigational Site

    Brandon, Florida

  • 205.372.01060 Boehringer Ingelheim Investigational Site

    Clearwater, Florida

  • 205.372.01069 Boehringer Ingelheim Investigational Site

    Miami Beach, Florida

  • 205.372.01023 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida

  • 205.372.01053 Boehringer Ingelheim Investigational Site

    Winter Park, Florida

  • 205.372.01045 Boehringer Ingelheim Investigational Site

    Calhoun, Georgia

  • 205.372.01043 Boehringer Ingelheim Investigational Site

    Normal, Illinois

  • 205.372.01061 Boehringer Ingelheim Investigational Site

    Dubuque, Iowa

  • 205.372.01035 Boehringer Ingelheim Investigational Site

    Wichita, Kansas

  • 205.372.01049 Boehringer Ingelheim Investigational Site

    Shreveport, Louisiana

  • 205.372.01015 Boehringer Ingelheim Investigational Site

    Biddeford, Maine

  • 205.372.01067 Boehringer Ingelheim Investigational Site

    Columbia, Maryland

  • 205.372.01006 Boehringer Ingelheim Investigational Site

    Rockville, Maryland

  • 205.372.01013 Boehringer Ingelheim Investigational Site

    Detroit, Michigan

  • 205.372.01003 Boehringer Ingelheim Investigational Site

    Minneapolis, Minnesota

  • 205.372.01021 Boehringer Ingelheim Investigational Site

    Chesterfield, Missouri

  • 205.372.01014 Boehringer Ingelheim Investigational Site

    St Louis, Missouri

  • 205.372.01036 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 205.372.01046 Boehringer Ingelheim Investigational Site

    Albuquerque, New Mexico

  • 205.372.01024 Boehringer Ingelheim Investigational Site

    Mineola, New York

  • 205.372.01029 Boehringer Ingelheim Investigational Site

    Rochester, New York

  • 205.372.01030 Boehringer Ingelheim Investigational Site

    Syracuse, New York

  • 205.372.01026 Boehringer Ingelheim Investigational Site

    Chapel Hill, North Carolina

  • 205.372.01019 Boehringer Ingelheim Investigational Site

    Charlotte, North Carolina

  • 205.372.01027 Boehringer Ingelheim Investigational Site

    Elizabeth City, North Carolina

  • 205.372.01038 Boehringer Ingelheim Investigational Site

    Raleigh, North Carolina

  • 205.372.01031 Boehringer Ingelheim Investigational Site

    Winston-Salem, North Carolina

Showing 40 of 334 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.